COVID-19 and Cancer Consortium Registry (CCC19)
Status
Conditions
Treatments
Details and patient eligibility
About
In this study we will collect granular information on cancer patients infected with COVID-19, as rapidly as possible. The mechanism for collection of this information is a de-identified centralized registry housed at Vanderbilt University Medical Center, with data donations from internal and external health care professionals.
Full description
The COVID-19 and Cancer Consortium (CCC19) registry prospectively collects anonymized data about patients diagnosed with COVID-19 and cancer. The goal of the registry is to generate hypothesis-generating and hypothesis-supporting findings that are generalizable to the population at large. Specifically:
I. Characterize patient factors, such as pre-existing comorbidities, baseline medication exposures, cancer type, status, and treatment, and demographic factors that are associated with short- and long-term outcomes of COVID-19 (laboratory-confirmed or presumptive), including severity and fatality, in patients with cancer.
II. Describe cancer treatment modifications made in response to COVID-19, including dose adjustments, changes in symptom management, or temporary or permanent cessation.
III. Evaluate the association of COVID-19 with cancer outcomes.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
• Healthcare providers or their proxies who would like to report a patient with ALL of the following criteria:
- Suspected (presumptive positive based on clinical presentation) or lab-confirmed COVID-19.
- Current or past medical history of invasive malignancy (any type)
Exclusion criteria
- Participants at international sites not explicitly listed below
- Non-healthcare providers (or their proxies)
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal